CClinicalTrials.gg
Status unknownNCT03090074LOWinCHIPUpdated Oct 15, 2019

Moderate or Extensive Carbohydrate Reduction in Risk Patients

An interventional study of Diet regime and Type of psychological support in Glucose Metabolism Disorders, sponsored by University Hospital, Linkoeping. Status unknown at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-15.

Sponsored by University Hospital, Linkoeping · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2019), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Risk-patients for diabetes or patients that are diagnosed with this condition but who are not treated with insulin are randomized two times, according to diet and according to the type of support:

Randomization with regard to carbohydrate restriction (25-30 E% or \< 10E%). Randomization with regard to type of psychological support. Either according to Acceptance and Commitment Therapy or to traditional cognitive behavioral therapy. Both kinds of psychological support is given as group therapy.

Two-hundred patients are recruited and each patient is followed for two years.

Read the detailed description

The organizers will recruit 200 patients in the study "To lower glucose levels and reduce weight by exclusion of carbohydrates and inclusion of psychological behavioral support" (LOWinCHIP) at the primary care health center "Cithyhälsan Centrum" in Norrköping. Each patient will be followed for 2 years. Patients are eligible if they have are above 18 years of age and have a BMI above 28 kg/m2 and also belong to one or more of the following groups: 1) type 2 diabetes that is not treated with insulin. 2) Patients that have had gestational diabetes or who have 3) first grade relative with type 2 diabetes. Finally 4) pre-diabetic individuals with impaired fasting glucose (6.1-6.9 mmol) or impaired glucose tolerance (capillary plasma glucose 8.9-12-1 after glucose challenge) are also potential participants. Patients must not have insulin therapy or severe kidney failure (GFR\< 30). They can also not have severe physical restrictions for activity and they must not have difficulties with understanding written Swedish texts.

The participants are randomized two times (two by two factorial):

Randomization with regard to carbohydrate restriction (25-30 E% or \< 10E%). Randomization with regard to type of psychological support. Either according to Acceptance and Commitment Therapy (ACT) or to traditional cognitive behavioral therapy. Each group will have three group sessions with approximately 8 participants followed by a telephone call by the therapist. Each session will be held by the psychologists that are part of the Cityhälsan Centrum staff.

The study has > 95% power to demonstrate 5% HbA1c (mmol/mol) difference between groups with a drop out of 25%.

02

Conditions studied

  • Glucose Metabolism Disorders
03

In context

Metabolic Diseases

997 studies on the registry are indexed under Metabolic Diseases; 234 are open to participants now.

This study's planned enrollment of 200 is above the median of 48 across 670 interventional studies indexed under Metabolic Diseases.

Browse Metabolic Diseases studies →

Lead sponsor

University Hospital, Linkoeping is the lead sponsor of 118 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diabetes without insulin. Patients at high risk for developing diabetes.

Exclusion criteria

Exclusion Criteria:

  • Severe kidney failure. Insulin therapy. Inability to understand instructions.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    Moderate carbohydrate restriction and traditional support

    Moderate carbohydrate restriction and traditional support with group meetings

    Behavioral: Diet regime · Behavioral: Type of psychological support

  • Active comparator
    Extreme low carbohydrate diet and traditional support

    Extreme carbohydrate restriction and traditional support with group meetings

    Behavioral: Diet regime · Behavioral: Type of psychological support

  • Active comparator
    Moderate carbohydrate restriction and ACT support

    Moderate carbohydrate restriction and psychological support based on acceptance and commitment therapy

    Behavioral: Diet regime · Behavioral: Type of psychological support

  • Active comparator
    Extreme carbohydrate restriction and ACT support

    Extreme carbohydrate restriction and psychological support based on acceptance and commitment therapy

    Behavioral: Diet regime · Behavioral: Type of psychological support

Interventions

  • BehavioralDiet regime

    Randomization to moderate or extreme low-carbohydrate Mediterranean diet advice.

  • BehavioralType of psychological support

    Randomization to group-based psychological support according to ACT or to traditional cognitive behavioral therapy

06

What researchers measure

Primary outcomes

  1. Long-term glucose levels

    HbA1c levels

    Time frame: 2 years

Secondary outcomes

  1. Quality of Life

    Quality of Life by questionnaires

    Time frame: 2 years

  2. Cardiovascular risk factors

    Lipids, body weight, glucose, ketones

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
  • University Hospital of Linkoping
    Linkoping, 58185, Sweden
    • Fredrik H Nystrom, MD, prof. · Contact
    • Fredrik H Nystrom, MD PhD prof · Principal investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — It is not planned to be shared

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03090074
Lead sponsor
University Hospital, Linkoeping
Responsible party
Fredrik H Nystrom (Professor, head of Internal Medicine, consultant in Endocrinology., University Hospital, Linkoeping) — Principal investigator
First posted
Mar 24, 2017
Start date
Mar 20, 2017
Primary completion
Mar 19, 2021 (estimated)
Completion
Mar 19, 2021 (estimated)
Last update
Oct 15, 2019

Study contacts

Fredrik H Nystrom, professor
Contact
fredrik.h.nystrom@gmail.com
736569303 ext. +46

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion